- Home
- EARN vs INBX Comparison
EARN vs INBX Comparison
Compare EARN & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EARN
- INBX
- Stock Information
- Founded
- EARN 2012
- INBX 2010
- Country
- EARN United States
- INBX United States
- Employees
- EARN N/A
- INBX N/A
- Industry
- EARN Real Estate Investment Trusts
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- EARN Real Estate
- INBX Health Care
- Exchange
- EARN Nasdaq
- INBX Nasdaq
- Market Cap
- EARN 187.6M
- INBX 168.1M
- IPO Year
- EARN 2013
- INBX 2020
- Fundamental
- Price
- EARN $5.37
- INBX $11.18
- Analyst Decision
- EARN Buy
- INBX Hold
- Analyst Count
- EARN 2
- INBX 1
- Target Price
- EARN $5.88
- INBX N/A
- AVG Volume (30 Days)
- EARN 452.8K
- INBX 97.5K
- Earning Date
- EARN 05-20-2025
- INBX 05-20-2025
- Dividend Yield
- EARN 17.89%
- INBX 7.56%
- EPS Growth
- EARN N/A
- INBX N/A
- EPS
- EARN 0.28
- INBX 112.62
- Revenue
- EARN $41,240,000.00
- INBX $200,000.00
- Revenue This Year
- EARN N/A
- INBX N/A
- Revenue Next Year
- EARN $16.66
- INBX N/A
- P/E Ratio
- EARN $19.21
- INBX $0.10
- Revenue Growth
- EARN N/A
- INBX N/A
- 52 Week Low
- EARN $4.33
- INBX $10.80
- 52 Week High
- EARN $7.26
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- EARN 48.29
- INBX 38.27
- Support Level
- EARN $5.33
- INBX $10.90
- Resistance Level
- EARN $5.48
- INBX $12.60
- Average True Range (ATR)
- EARN 0.13
- INBX 0.86
- MACD
- EARN 0.02
- INBX -0.03
- Stochastic Oscillator
- EARN 23.91
- INBX 14.28
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.